At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 132 enrolled
Drug / intervention
MP1032 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multicenter, Proof-of-concept, Phase IIA Study of MP1032 Plus Standard of Care vs Standard of Care in the Treatment of Hospitalized Participants With Moderate to Severe COVID-19
In Brief
A Phase 2 clinical trial evaluating MP1032 and Placebo for COVID-19. Completed, enrolled 132 participants across 31 sites in 7 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of MP1032 with standard of care (SoC) verses placebo with SoC in hospitalized adults participants with moderate to severe coronavirus disease 2019 (COVID-19).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesBulgaria, France, Hungary, Italy, Romania, Spain, United States
CollaboratorsSyneos Health
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartOct 2021
Primary CompletionJul 2022
Study CompletionSep 2022
TodayJul 2026
First PostedJun 21, 2021
Enrollment StartOct 19, 2021
Primary CompletionJul 28, 2022
Study CompletionSep 5, 2022
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.0 years ago
Interventions
MP1032drug
Hard gelatin capsules for oral administration.
Placebodrug
Placebo capsules matched to MP1032 for oral administration.